Home › Funds › Paradigm Biocapital Advisors LP › GMAB
Paradigm Biocapital Advisors LP position in GMAB
GENMAB A/S · Health Care
Paradigm Biocapital Advisors LP reported holding 14,136,472 shares of GMAB (GENMAB A/S) in its Q3 2026 13F filing — a position valued at US$504.3M, representing 10.03% of its reported portfolio and ranking #2 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed GMAB holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Paradigm Biocapital Advisors LP's GMAB position evolved
Paradigm Biocapital Advisors LP first disclosed a stake in GMAB in Q3 2025 at 3,816,851 shares (US$117.1M). The position peaked in Q3 2026 at 14,136,472 shares, worth US$504.3M. Across 5 filings, Paradigm Biocapital Advisors LP increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 14,136,472 shares valued at US$504.3M — an increase of 1,003,341 shares quarter over quarter.. Notable position changes include a 84% increase in Q4 2025 (shares fell 13% over the following quarter), a 65% increase in Q2 2026 (shares rose 30% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 3.82M | $117.06M | New |
| Q4 2025 | 7.04M | $216.83M | Add |
| Q1 2026 | 7.97M | $213.78M | Add |
| Q2 2026 | 13.13M | $360.77M | Add |
| Q3 2026 | 14.14M | $504.32M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GMAB and 13F data
GMAB (GENMAB A/S) is a Health Care company. 36 other funds we track also report a position in GMAB — the largest reported positions include Orbis Allan Gray Ltd (US$377.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$188.6M), Sofinnova Investments, Inc. (US$155.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GMAB
- Orbis Allan Gray Ltd 10.57M sh · $376.99M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 6.87M sh · $188.58M · Q2 2026
- Sofinnova Investments, Inc. 4.35M sh · $155.17M · Q3 2026
- HARDING LOEVNER LP 2.90M sh · $134.23M · Q3 2026
- Deep Track Capital, LP 2.76M sh · $98.46M · Q3 2026
- DIADEMA PARTNERS LP 518.10K sh · $18.48M · Q3 2026
More on Paradigm Biocapital Advisors LP
FAQ
How long has Paradigm Biocapital Advisors LP held GMAB?
Paradigm Biocapital Advisors LP has disclosed GMAB holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Paradigm Biocapital Advisors LP's current position in GMAB?
As of Q3 2026, Paradigm Biocapital Advisors LP holds 14.14M shares of GMAB (GENMAB A/S), valued at $504.32M, representing 10.03% of its reported portfolio and ranking #2.
Has Paradigm Biocapital Advisors LP been buying or selling GMAB?
In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP increased its position in GMAB. The position peaked in Q3 2026 at 14.14M shares.
Which other funds hold GMAB?
Other major institutional holders of GMAB include Orbis Allan Gray Ltd, DEERFIELD MANAGEMENT COMPANY, L.P., Sofinnova Investments, Inc., among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.